Phase 3 study of REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients.

Trial Profile

Phase 3 study of REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 16 Nov 2017 According to an Oncolytics Biotech media release, the Company expects to have formal guidance back from the European Medicines Agency (EMA) before the end of the year and to begin enrolling patients in this study in mid-2018.
    • 20 Sep 2017 New trial record
    • 19 Sep 2017 According to an Oncolytics Biotech media release, data of this study will be used for to support a future Biologics License Application (BLA) submission.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top